中华耳鼻咽喉头颈外科杂志
中華耳鼻嚥喉頭頸外科雜誌
중화이비인후두경외과잡지
CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY
2011年
8期
675-680
,共6页
万仁强%李湘平%王路%鲁娟%罗花南%李刚%刘雄%张宝
萬仁彊%李湘平%王路%魯娟%囉花南%李剛%劉雄%張寶
만인강%리상평%왕로%로연%라화남%리강%류웅%장보
爱泼斯坦巴尔病毒核抗原%鼻咽肿瘤%细胞增殖%细胞周期
愛潑斯坦巴爾病毒覈抗原%鼻嚥腫瘤%細胞增殖%細胞週期
애발사탄파이병독핵항원%비인종류%세포증식%세포주기
Epstein-Barr virus nuclear antigens%Nasopharyngeal neoplasms%Cell proliferation%Cell cycle
目的 研究EB病毒核抗原1(Epstein-Barr virus nuclear antigen 1,EBNA1)对人鼻咽癌细胞增殖及细胞周期的影响.方法 构建特异性的短发夹RNA(short hairpin RNA,shRNA)EBNA1慢病毒干扰载体,包装慢病毒后感染过表达EBNA1的鼻咽癌细胞C666-EBNA1(简写为CE).应用四甲基偶氮唑蓝法(MTT)和细胞计数法检测细胞增殖状态,流式细胞术、荧光定量PCR及蛋白免疫印迹法检测细胞周期及相关调控因子变化.结果 成功构建含shRNA EBNA1的重组慢病毒,其感染可显著下调CE细胞中EBNA1表达.细胞计数和MTT均证明CE-shRNA细胞的增殖能力较CE-对照组显著下降(P值均<0.05).细胞周期提示干扰EBNA1后CE细胞G0-G1期比例由(62.43±6.62)%升高到(89.66±0.64)%,两者比较差异有统计学意义(t=-7.091,P=0.002),S期比例由(34.93±7.36)%下降为(7.82±2.44)%,两者比较差异有统计学意义(t=6.095,P=0.004),G2-M期无明显变化(t=0.090,P=0.933).抑制EBNA1后,c-myc、CDK4、CDK6、pRb的mRNA水平分别下调65.60%、34.06%、41.05%、55.29%.蛋白免疫印迹法证实抑制EBNA1后4种蛋白的表达亦下调.结论 沉默EBNA1基因可抑制鼻咽癌细胞增殖,其机制之一可能是通过影响c-myc、CDK4、CDK6、pRb等基因的表达使鼻咽癌细胞阻滞于G0-G1期.
目的 研究EB病毒覈抗原1(Epstein-Barr virus nuclear antigen 1,EBNA1)對人鼻嚥癌細胞增殖及細胞週期的影響.方法 構建特異性的短髮夾RNA(short hairpin RNA,shRNA)EBNA1慢病毒榦擾載體,包裝慢病毒後感染過錶達EBNA1的鼻嚥癌細胞C666-EBNA1(簡寫為CE).應用四甲基偶氮唑藍法(MTT)和細胞計數法檢測細胞增殖狀態,流式細胞術、熒光定量PCR及蛋白免疫印跡法檢測細胞週期及相關調控因子變化.結果 成功構建含shRNA EBNA1的重組慢病毒,其感染可顯著下調CE細胞中EBNA1錶達.細胞計數和MTT均證明CE-shRNA細胞的增殖能力較CE-對照組顯著下降(P值均<0.05).細胞週期提示榦擾EBNA1後CE細胞G0-G1期比例由(62.43±6.62)%升高到(89.66±0.64)%,兩者比較差異有統計學意義(t=-7.091,P=0.002),S期比例由(34.93±7.36)%下降為(7.82±2.44)%,兩者比較差異有統計學意義(t=6.095,P=0.004),G2-M期無明顯變化(t=0.090,P=0.933).抑製EBNA1後,c-myc、CDK4、CDK6、pRb的mRNA水平分彆下調65.60%、34.06%、41.05%、55.29%.蛋白免疫印跡法證實抑製EBNA1後4種蛋白的錶達亦下調.結論 沉默EBNA1基因可抑製鼻嚥癌細胞增殖,其機製之一可能是通過影響c-myc、CDK4、CDK6、pRb等基因的錶達使鼻嚥癌細胞阻滯于G0-G1期.
목적 연구EB병독핵항원1(Epstein-Barr virus nuclear antigen 1,EBNA1)대인비인암세포증식급세포주기적영향.방법 구건특이성적단발협RNA(short hairpin RNA,shRNA)EBNA1만병독간우재체,포장만병독후감염과표체EBNA1적비인암세포C666-EBNA1(간사위CE).응용사갑기우담서람법(MTT)화세포계수법검측세포증식상태,류식세포술、형광정량PCR급단백면역인적법검측세포주기급상관조공인자변화.결과 성공구건함shRNA EBNA1적중조만병독,기감염가현저하조CE세포중EBNA1표체.세포계수화MTT균증명CE-shRNA세포적증식능력교CE-대조조현저하강(P치균<0.05).세포주기제시간우EBNA1후CE세포G0-G1기비례유(62.43±6.62)%승고도(89.66±0.64)%,량자비교차이유통계학의의(t=-7.091,P=0.002),S기비례유(34.93±7.36)%하강위(7.82±2.44)%,량자비교차이유통계학의의(t=6.095,P=0.004),G2-M기무명현변화(t=0.090,P=0.933).억제EBNA1후,c-myc、CDK4、CDK6、pRb적mRNA수평분별하조65.60%、34.06%、41.05%、55.29%.단백면역인적법증실억제EBNA1후4충단백적표체역하조.결론 침묵EBNA1기인가억제비인암세포증식,기궤제지일가능시통과영향c-myc、CDK4、CDK6、pRb등기인적표체사비인암세포조체우G0-G1기.
Objective To study the effect of Epstein-Barr virus nuclear antigen 1 ( EBNA1 ) on cell proliferation and cell cycle in nasopharyngeal carcinoma ( NPC ) cells. Methods Recombinant lentivirus that encoded EBNA1 short hairpin RNA (shRNA) was prepared. The C666-EBNA1 (CE) cells were transduced with lentivirus and selected by fluorescence activated cell sorting (FACS) to repress EBNA1 expression. The protein expression levels of EBNA1 were examined by Western blot. The effect of EBNA1 silence on cell proliferation was analyzed by MTT assay and cell growth assay, respectively. Cell cycle was assessed by flow cytometry. The mRNA and protein levels of cell cycle regulators were examined by real-time PCR and Western blot. Results Recombinant lentivirus encoded EBNA1 shRNA was successfully constructed. The EBNA1 expression in CE cells was significantly reduced by lentivirus-mediated RNA interference. The results of cell counting and MTT assay showed that EBNA1 down-regulation significantly inhibited cell growth in CE-shRNA EBNA1 cells ( P < 0. 05 ). Compared with the control group, the percentage of cells in G0-G1 phase was increased from ( 62.43 ± 6. 62 ) % to ( 89. 66 ± 0. 64 ) % ( t=-7.091, P=0.002), and that in S phase was decreased from (34.93 ±7.36)% to (7.82 ±2.44)%(t = 6. 095, P = 0. 004 ). The mRNA expressions of c-myc, CDK4, CDK6 and pRb were decreased by 65. 60%, 34. 06%, 41.05% and 55.29% respectively with the similar results in protein expression levels.Conclusions Suppression of EBNA1 may inhibit the growth of nasopharyngeal carcinoma cells in vitro and induce a G1-phase cell cycle arrest, which might be mediated by down-regulation of c-myc, CDK4, CDK6 and pRb.